Severe Congenital Neutropenia (Kostmann Disease)
A rare inherited disorder marked by very low neutrophil counts from birth, causing severe bacterial infections and requiring lifelong specialist management.
- Inherited neutrophil disorder
- G-CSF therapy access
- Transplant for refractory disease
- Typical Age at Diagnosis
- Infancy
- Inheritance
- AD (ELANE) or AR (HAX1, G6PC3)
- Key Risk
- Severe bacterial infections; MDS/AML over time
- Advanced Therapies
- G-CSF, stem cell transplant
What Is Severe Congenital Neutropenia?
Severe congenital neutropenia (SCN) is a group of rare inherited disorders in which the bone marrow fails to produce enough neutrophils, the white blood cells essential for fighting bacterial infections. Children with SCN are born with this defect, and most are diagnosed in infancy after recurrent fevers, skin infections, or abscesses.
The classic form, originally described by Kostmann and most often linked to HAX1 mutations, is inherited in an autosomal recessive pattern. More commonly today, SCN is caused by autosomal dominant mutations in the ELANE gene, with G6PC3 mutations accounting for a further subset, sometimes accompanied by heart or urinary tract abnormalities.
With modern treatment, most children with SCN can live active lives, though lifelong monitoring is needed because of an elevated long-term risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Genetic Subtypes of Severe Congenital Neutropenia
SCN is genetically heterogeneous, with several genes implicated in disrupting normal neutrophil production.
Symptoms and Signs
Most infants with SCN present with recurrent, severe bacterial infections in the first months of life.
Causes and Risk Factors
SCN arises from inherited mutations that disrupt the maturation of neutrophil precursors in the bone marrow.
Diagnosis and Investigations
Diagnosis requires confirming persistent severe neutropenia and identifying the underlying genetic cause.
Disease Risk Stratification
SCN is not formally staged, but clinicians stratify ongoing risk based on response to treatment and marrow surveillance findings.
Standard Treatment Approach
Treatment focuses on raising the neutrophil count and managing infections proactively.
Advanced and Emerging Treatment Options
Most children respond well to growth factor therapy, but transplant remains the only curative option for refractory or transformed disease.
Growth Factor Therapy
Granulocyte Colony-Stimulating Factor (G-CSF)
First-line therapy that stimulates neutrophil production and dramatically reduces infection frequency in most patients.
Cellular Therapy
Allogeneic Hematopoietic Stem Cell Transplant
Curative option reserved for G-CSF-refractory disease or transformation to MDS/AML.
Precision Medicine
Genetic Subtype-Guided Surveillance
Tailoring monitoring intensity based on the specific gene involved (ELANE, HAX1, G6PC3) to anticipate associated complications.
Research
Gene Therapy Approaches
Early research is exploring gene correction strategies for inherited neutropenia syndromes, though this remains investigational.
Biomarkers and Precision Medicine
Genetic and marrow findings guide treatment intensity and surveillance.
When a Second Opinion May Be Important
Specialist input can be valuable at several points in the management of severe congenital neutropenia.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With G-CSF therapy, most children with SCN experience a dramatic reduction in serious infections and can lead active lives. Long-term outlook depends on response to treatment and ongoing surveillance for clonal evolution.
Supportive Care and Living With Severe Congenital Neutropenia
Day-to-day management focuses on infection prevention and consistent specialist follow-up.
How CancerFax Helps You Explore Treatment Options
We help families with severe congenital neutropenia access specialist review of marrow and genetic reports, connect with experienced pediatric hematology centers, and coordinate second opinions when transplant is being considered.
Get a free case reviewFrequently Asked Questions
It is a rare inherited disorder in which the bone marrow cannot produce enough neutrophils, leading to severe bacterial infections from infancy.
The classic form is caused by mutations in the HAX1 gene, inherited in an autosomal recessive pattern, though other genes such as ELANE and G6PC3 also cause similar disease.
Early signs typically include recurrent fevers, skin abscesses, oral ulcers, and frequent infections in infancy.
The mainstay of treatment is daily G-CSF injections to stimulate neutrophil production, along with prompt infection management.
There is a long-term risk of progression to MDS or AML, particularly in patients who develop acquired marrow changes, which is why regular surveillance is important.
No. Transplant is generally reserved for children who do not respond well to G-CSF or who develop MDS/AML.
Diagnosis involves serial blood counts, bone marrow examination, and genetic testing to confirm the underlying mutation.
Yes, it can be inherited in autosomal dominant or recessive patterns depending on the gene involved, though some cases arise from new mutations.
Most specialists recommend annual or more frequent bone marrow exams with cytogenetics to detect early clonal changes.
Yes. CancerFax can help you arrange specialist review of medical reports, connect with experienced pediatric hematology centers, and coordinate second opinions and cross-border care when needed.
Get Specialist Guidance for Severe Congenital Neutropenia
Send your reports for review and explore treatment and second-opinion options with experienced specialists.